Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Flat with a negative bias
Mon, 20 Dec 11:30 am

After starting today's session on a negative note, Indian indices are still languishing in the red. Other key Asian markets too are trading weak. Currently, heavyweights in the Sensex are trading weak with stocks from the banking and healthcare space bearing investors' brunt. However, stocks from the auto and consumer durables space are trading firm.

Currently, the BSE-Sensex is trading down by around 45 points, while the NSE-Nifty is down by about 22 points. However, there has been some buying interest amongst the mid and small cap stocks as the BSE-Midcap and BSE-Smallcap indices are trading higher by 0.07% and 0.44% respectively.

Pharma stocks are trading weak with Dr Reddy's and Glenmark Pharma leading the pack of losers. However, Indoco Remedies and IPCA Labs are trading strong. On failure to update safety warnings on the information leaflets, UK's drug regulator has asked Ranbaxy Laboratories to recall three batches of ‘Pravastatin' an anti-cholesterol drug. As per the regulator the patient information leaflets were not updated to include approved safety warnings, as required by the European Medicines Agency. It may be noted that the drug regulator has also issued alert on few batches of Ranbaxy's Simvastatin 20 mg and 40 mg tablets a while ago. It may be noted that revenues from these drugs in the UK do not form a major part of Ranbaxy's overall revenues from its product portfolio. Hence, it is not likely to result in any major revenue losses to the company. That said, the company has been facing issues with regulators for a while now and its problems with the US FDA have not yet been fully resolved.

Hotel stocks are trading firm led by Country Club and EIH. As per a leading financial daily, SEBI has approved the rights issue of EIH Ltd. This is expected to see a renewed battle for control of the hotel chain. It may be recalled that Reliance Industries limited (RIL) had picked up a 14.80% stake in EIH in August while ITC has a stake of 14.98% and the promoters control 32.31% stake in the company. RIL is seen as a financial investor by the company, while ITC is seen as a potential threat. The Rs 13 bn rights issue presents an opportunity for both RIL and ITC to up their stake beyond 15% and make a bid for control of EIH. As per norms, any entity owning more than 15% in a company has to make a mandatory open offer for at least additional 20% stake.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Flat with a negative bias". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.